LU91147I2 - Pemetrexed et ses sels pharmaceutiquement acceptables. - Google Patents

Pemetrexed et ses sels pharmaceutiquement acceptables.

Info

Publication number
LU91147I2
LU91147I2 LU91147C LU91147C LU91147I2 LU 91147 I2 LU91147 I2 LU 91147I2 LU 91147 C LU91147 C LU 91147C LU 91147 C LU91147 C LU 91147C LU 91147 I2 LU91147 I2 LU 91147I2
Authority
LU
Luxembourg
Prior art keywords
pemetrexed
pharmaceutically acceptable
acceptable salts
salts
pharmaceutically
Prior art date
Application number
LU91147C
Other languages
English (en)
Original Assignee
Univ Princeton
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27503964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91147(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/528,155 external-priority patent/US5028608A/en
Application filed by Univ Princeton, Lilly Co Eli filed Critical Univ Princeton
Publication of LU91147I2 publication Critical patent/LU91147I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
LU91147C 1989-12-11 2005-03-14 Pemetrexed et ses sels pharmaceutiquement acceptables. LU91147I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44874289A 1989-12-11 1989-12-11
US47965590A 1990-02-08 1990-02-08
US07/528,155 US5028608A (en) 1989-12-11 1990-05-24 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives
US07/528,805 US4996206A (en) 1989-12-11 1990-05-24 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives

Publications (1)

Publication Number Publication Date
LU91147I2 true LU91147I2 (fr) 2005-05-17

Family

ID=27503964

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91147C LU91147I2 (fr) 1989-12-11 2005-03-14 Pemetrexed et ses sels pharmaceutiquement acceptables.

Country Status (22)

Country Link
EP (1) EP0432677B1 (fr)
JP (1) JP3016876B2 (fr)
CN (1) CN1030608C (fr)
AR (1) AR245129A1 (fr)
AT (1) ATE135007T1 (fr)
AU (1) AU640182B2 (fr)
CA (1) CA2031890C (fr)
CY (1) CY2076B1 (fr)
DE (2) DE122005000012I2 (fr)
DK (1) DK0432677T3 (fr)
ES (1) ES2084639T4 (fr)
GR (1) GR3019784T3 (fr)
HK (1) HK1000920A1 (fr)
HU (1) HU218483B (fr)
IE (1) IE904445A1 (fr)
IL (1) IL96531A (fr)
LU (1) LU91147I2 (fr)
NL (1) NL300181I2 (fr)
NZ (1) NZ236385A (fr)
PT (1) PT96140B (fr)
RU (1) RU2057131C9 (fr)
SG (1) SG48098A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254687A (en) 1991-12-04 1993-10-19 The Trustees Of Princeton University Process for the preparation of pyrrolo[2,3-d]pyrimidines
US5235053A (en) * 1992-06-22 1993-08-10 Eli Lilly And Company Process for the synthesis of 4-hydroxy-5-halopyrrold[2,3-d]pyrimidine intermediates
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
CN100344615C (zh) * 2004-11-25 2007-10-24 重庆医药工业研究院有限责任公司 制备N－(吡咯并[2,3－d]嘧啶－5－基)酰基谷氨酸衍生物的方法及中间体
BRPI0606480A (pt) 2005-01-21 2008-03-11 Astex Therapeutics Ltd compostos farmacêuticos
ES2356792T3 (es) 2006-08-14 2011-04-13 Sicor, Inc. Procedimientos para la preparación de sales farmacéuticamente aceptables liofilizadas de pemetrexed diácido.
WO2008021385A2 (fr) 2006-08-14 2008-02-21 Sicor Inc. Procédés de préparation de produits intermédiaires de pemetrexed
KR20090052355A (ko) 2006-08-14 2009-05-25 시코르, 인크. 순도가 높은 페메트렉세드 이산 및 이의 제조 방법
ES2354843T3 (es) 2006-08-14 2011-03-18 Sicor, Inc. Formas cristalinas de diácido de pemetrexed y procedimientos para la preparación de las mismas.
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CN101417998B (zh) 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
AU2015210337B2 (en) * 2008-06-06 2017-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical combination
HUE037291T2 (hu) * 2008-06-06 2018-08-28 Boehringer Ingelheim Int Gyógyászati kombináció
CN101684121B (zh) * 2008-09-22 2013-04-03 重庆医药工业研究院有限责任公司 培美曲塞二酸的新晶型及其制备方法
US9174991B2 (en) 2009-11-24 2015-11-03 Azad Pharmaceutical Ingredients Ag Crystalline form of pemetrexed disodium
LT2854768T (lt) 2012-05-30 2017-06-12 Fresenius Kabi Oncology Limited Pemetreksedo farmacinės kompozicijos
ITRM20120398A1 (it) 2012-08-08 2014-02-09 Berlin Chemie Ag Procedimento di sintesi pemetrexed e suo sale di lisina.
US20160051679A1 (en) 2013-04-12 2016-02-25 Actavis Group Ptc Ehf. Pemetrexed Formulation
EP2997031A1 (fr) 2013-05-17 2016-03-23 Instytut Farmaceutyczny Procédé pour la préparation de pemetrexed disodique amorphe de haute pureté et formes cristallines de l'acide n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)éthyl]benzoyl]-l-glutamique
JP6248189B2 (ja) 2013-06-14 2017-12-13 シントン・ベスローテン・フェンノートシャップ 安定な抗がん剤のアルギニン塩とそれを含む組成物
EP3021849B1 (fr) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Nouvelles formes cristallines de sels de trométhamine de pemetrexed
NZ630292A (en) 2013-11-25 2015-02-27 Shilpa Medicare Ltd Process for crystalline pemetrexed dipotassium salt
PL3206666T3 (pl) 2014-10-16 2020-09-21 Synthon B.V. Ciekła kompozycja farmaceutyczna zawierająca pemetreksed
CN104672241B (zh) * 2015-01-29 2018-04-24 王磊 吡咯并[2,3-d]嘧啶类化合物及其用途
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR20230042756A (ko) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. 고형 종양의 치료에 사용하기 위한 lsd1 억제제의 조합물
US10793573B2 (en) * 2017-08-31 2020-10-06 Duquesne University Of The Holy Spirit First-in-class of SHMT2 and MTHFD2 inhibitors as antitumor agents
CN110305137A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305135B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305136A (zh) * 2018-03-20 2019-10-08 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法
CN110305134B (zh) * 2018-03-20 2022-02-22 鲁南制药集团股份有限公司 一种培美曲塞二钠中间体及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4818819A (en) * 1986-10-20 1989-04-04 The Trustees Of Princeton University Process for the preparation of fused pyridine compounds
NO169490C (no) * 1988-03-24 1992-07-01 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive pyrrolopyrimidinderivater
DK172753B1 (da) * 1988-05-25 1999-06-28 Lilly Co Eli N-(5,6,7,8-tetrahydropyrido[2,3--d]pyrimidin-6-yl-alkanoyl)-glutaminsyrederivater, deres anvendelse, farmaceutiske præparat
US4883799A (en) * 1988-06-29 1989-11-28 The Trustees Of Princeton University N-(4-(1-hydroxy-3-(5,6,7,8-tetrahydropyrido(2,3,-d)-pyrimidin-6-yl)prop-2-yl)benzoyl)glutamic acid derivatives

Also Published As

Publication number Publication date
HU218483B (hu) 2000-09-28
IL96531A (en) 1995-08-31
PT96140B (pt) 1997-06-30
IE904445A1 (en) 1991-06-19
IL96531A0 (en) 1991-09-16
EP0432677A1 (fr) 1991-06-19
GR3019784T3 (en) 1996-07-31
NL300181I1 (nl) 2005-05-02
CN1030608C (zh) 1996-01-03
CN1055182A (zh) 1991-10-09
NZ236385A (en) 1992-05-26
AR245129A1 (es) 1993-12-30
JP3016876B2 (ja) 2000-03-06
RU2057131C9 (ru) 2006-04-10
SG48098A1 (en) 1998-04-17
DE122005000012I2 (de) 2006-02-09
HU908147D0 (en) 1991-06-28
HUT58335A (en) 1992-02-28
DE69025723D1 (de) 1996-04-11
NL300181I2 (nl) 2005-06-01
EP0432677B1 (fr) 1996-03-06
PT96140A (pt) 1991-09-30
AU6779190A (en) 1991-06-13
AU640182B2 (en) 1993-08-19
DE69025723T2 (de) 1996-10-31
ES2084639T3 (es) 1996-05-16
RU2057131C1 (ru) 1996-03-27
ATE135007T1 (de) 1996-03-15
DK0432677T3 (da) 1996-04-09
HK1000920A1 (en) 1998-05-08
JPH083166A (ja) 1996-01-09
DE122005000012I1 (de) 2005-06-23
CA2031890C (fr) 2000-07-25
CA2031890A1 (fr) 1991-06-12
ES2084639T4 (es) 2013-06-11
CY2076B1 (en) 1998-09-11

Similar Documents

Publication Publication Date Title
LU91147I2 (fr) Pemetrexed et ses sels pharmaceutiquement acceptables.
LU91452I2 (fr) "Mycafungine et ses sels pharmaceutiquement acceptables(MYCAMINEr)"
LU90829I2 (fr) Tepoxalin-zubrin et ses d-riv-s pharmaceutiquement acceptables
LU90484I2 (fr) Novorapid - insuline asparte et ses sels et derives pharmaceutiquement acceptables
LU90736I2 (fr) Agenerase-amprenavir et ses d-riv-s pharmaceutiquement acceptables
LU91076I2 (fr) Tulathromycin et ses sels pharmaceutiquement acceptables (draxxin).
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
LU88576I2 (fr) RISPERIDONE et ses sels pharmaceutiquement acceptables (Risperdal R)
LU91039I2 (fr) Proteq flu et ses dérivés pharmaceutiquement acceptables
NO2001002I1 (no) Lamivudin, eventuelt i form av et farmasøytisk godtgbart salt
LU90069I2 (fr) Lercanidipine et ses sels et dérivés pharmaceutiquement acceptables (Zanidip)
TR24808A (tr) Darbe yutucu parca
MC2263A1 (fr) Aminobenzodiazepines et leurs sels pharmaceutiquement acceptables
FI950908A0 (fi) Antitussiivi
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
FI920631A0 (fi) Polymer med hoegt tg-vaerde och aoterdispergerbart pulver foer anvaendning i hydrauliskt portland- cementmurbruk och -betong.
DE68921951D1 (de) Kugelstirnfräser.
FI890968A (fi) Behaollarlock med loestagbar kolv och med saodant lock foersedd spridningsbehaollare.
LU88790I2 (fr) Moxidectin et ses dérivés pharmaceutiquement acceptables
FI890745A0 (fi) Kyltorn med laog silhuett och med fyllstrut med trapetsform.
LU88574I2 (fr) CEFEPIME et ses sels pharmaceutiquement acceptables (Maxipime R)
DE58900620D1 (de) Walzenschuesselmuehle.
IT8920405A0 (it) Aminoimidazopiridine farmacologicamente attive.
LU90110I2 (fr) Penciclovir et ses dérivés pharmaceutiquement acceptables
FI890824A0 (fi) Foerfarande foer framstaellning av skivor av mineralglas med hoeg genomslaeppning i det synliga spektralomraodet och laog genomslaeppning av solenergi och med detta foerfarande framstaellda skivor.